Gd(iii)–Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy-Reference-Cited by-同舟云学术

Gd(iii)–Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy

Published:2020 Issue:9 Volume:11 Page:2524-2530
ISSN:2041-6520
Container-title:Chemical Science
language:en
Short-container-title:Chem. Sci.

Author:

Adams Casey J.¹²³⁴^ORCID,Meade Thomas J.¹²³⁴^ORCID

Affiliation:

1. Departments of Chemistry, Molecular Biosciences, Neurobiology, and Radiology

2. Northwestern University

3. Evanston

4. USA

Abstract

The first example of Gd(iii)–Pt(iv) theranostic agents that are intracellularly reduced to provide MR contrast enhancement with simultaneous Pt(ii) chemotherapy.

Funder

National Cancer Institute

Ames Research Center

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2020/SC/C9SC05937G

Reference46 articles.

1. Cisplatin in cancer therapy: Molecular mechanisms of action

2. Particular aspects of platinum compounds used at present in cancer treatment

3. The Molecular Perspective: Cisplatin

4. The resurgence of platinum-based cancer chemotherapy

5. The status of platinum anticancer drugs in the clinic and in clinical trials

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances on Pt-Based Compounds for Theranostic Applications;Molecules;2024-07-23

2. Key Insights on the Classification and Theranostic Applications of Magnetic Resonance Imaging Contrast Agents;ChemMedChem;2024-02-06

3. Riding the metal wave: A review of the latest developments in metal-based anticancer agents;Coordination Chemistry Reviews;2024-02

4. Fluorogenic platinum(iv) complexes as potential predictors for the design of hypoxia-activated platinum(iv) prodrugs;Dalton Transactions;2024

5. A multi-spectroscopic and molecular docking approach for DNA/protein binding study and cell viability assay of first-time reported pendent azide bearing Cu(II)-quercetin and dicyanamide bearing Zn(II)-quercetin complexes;Heliyon;2023-12